Shares of GSK PLC GSK rose 1.11% to £13.62 Thursday, on what proved to be an all-around favorable trading session for the ...

GSK -4178116 (GSK4178116A) is under development for the prevention of varicella (chickenpox) caused by the new strain (US) of varicella-zoster virus (VZV). It is administered through subcutaneous ...

Drugmaker GSK said, a stamp has been released by India Post to commemorate its 100 years in India. The ₹5 denomination stamp ...

On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on ...

GSK took center stage last month, forming standout partnerships and alliances across multiple therapeutic areas.

Belantamab mafodotin is under clinical development by GSK and currently in Phase I for Systemic Lupus Erythematosus.

While some investors are already well versed in financial metrics (hat tip), this article is for those who would ...

GSK's Nucala gets China approval for chronic rhinosinusitis with nasal polyps; awaits FDA decision for COPD in May as it ...

On Friday, GSK plc (GSK) stock saw a decline, ending the day at $33.47 which represents a decrease of $-0.48 or -1.41% from the prior close of $33.95. The stock opened at $33.98 and touched a low of ...

GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that targets ...

China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...

Which biotechs are most likely to be acquired near-term? We asked Seeking Alpha analysts Edmund Ingham and Terry Chrisomalis for their thoughts on the topic. Read more here.